Oxford Nanopore and bioMérieux Unveil AmPORE-TB for Drug-Resistant TB Analysis

Oxford Nanopore Technologies and bioMérieux have launched AmPORE-TB, a sequencing-based tool for examining drug-resistant tuberculosis (TB). The system promises rapid identification of mutations linked to antimicrobial resistance in Mycobacterium tuberculosis through Oxford Nanopore's sequencing technology.

TB remains a leading cause of death globally, with multidrug-resistant strains affecting 400,000 people annually. WHO emphasizes the need for swift antimicrobial tests. AmPORE-TB stands out as one of three methods that meet WHO's criteria for identifying antimicrobial resistance gene mutations.

This RUO solution, operated on GridION devices, characterizes 24 TB-resistant genes swiftly and offers automated results on the same day. Targeting regions with high TB incidence, AmPORE-TB focuses on aiding low- and middle-income countries.